| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Peter K Stys | |
| P433 | issue | 1-2 | |
| P921 | main subject | prevention | Q1717246 |
| P304 | page(s) | 3-13 | |
| P577 | publication date | 2005-06-01 | |
| P1433 | published in | Journal of the Neurological Sciences | Q6296168 |
| P1476 | title | General mechanisms of axonal damage and its prevention | |
| P478 | volume | 233 |
| Q46970001 | A concerted role of Na+ -K+ -Cl- cotransporter and Na+/Ca2+ exchanger in ischemic damage |
| Q37403813 | A painful neuropathy-associated Nav1.7 mutant leads to time-dependent degeneration of small-diameter axons associated with intracellular Ca2+ dysregulation and decrease in ATP levels. |
| Q38593055 | A review of genome-wide association studies for multiple sclerosis: classical and hypothesis-driven approaches. |
| Q38237032 | A unified cell biological perspective on axon-myelin injury |
| Q46906898 | Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system |
| Q30532624 | Activity-dependent regulation of mitochondrial motility by calcium and Na/K-ATPase at nodes of Ranvier of myelinated nerves |
| Q42154248 | Acute anoxic changes in peripheral nerve: anatomic and physiologic correlations |
| Q52096505 | Adenosine Triphosphate Metabolism Measured by Phosphorus Magnetic Resonance Spectroscopy: A Potential Biomarker for Multiple Sclerosis Severity. |
| Q37256701 | Advancement of therapies for neuroprotection in multiple sclerosis |
| Q41570562 | Altered Functionality, Morphology, and Vesicular Glutamate Transporter Expression of Cortical Motor Neurons from a Presymptomatic Mouse Model of Amyotrophic Lateral Sclerosis. |
| Q35836853 | Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial |
| Q47417640 | Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial |
| Q48263280 | An energy theory of glaucoma |
| Q37778062 | Approaches to neuroprotective strategies in multiple sclerosis |
| Q55618808 | Arachidonic acid derivatives and their role in peripheral nerve degeneration and regeneration. |
| Q45363560 | Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients |
| Q36897647 | Autophagy protects against hypoxic injury in C. elegans |
| Q36285969 | Axon degeneration mechanisms: commonality amid diversity |
| Q39017694 | Axonal Excitability in Amyotrophic Lateral Sclerosis : Axonal Excitability in ALS. |
| Q36142095 | Axonal damage and outcome in subarachnoid haemorrhage. |
| Q35633387 | Axonal degeneration is mediated by the mitochondrial permeability transition pore. |
| Q34066839 | Axonal transport rate decreased at the onset of optic neuritis in EAE mice |
| Q33639466 | Calcium release from intra-axonal endoplasmic reticulum leads to axon degeneration through mitochondrial dysfunction |
| Q35853846 | Calcium signaling is implicated in the diffuse axonal injury of brain stem. |
| Q37960199 | Cannabinoids, multiple sclerosis and neuroprotection |
| Q31014030 | Changes observed in multiple sclerosis using magnetic resonance imaging reflect a focal pathology distributed along axonal pathways |
| Q24628273 | Cold paresis in multifocal motor neuropathy |
| Q35087742 | Complex I subunit gene therapy with NDUFA6 ameliorates neurodegeneration in EAE |
| Q33735496 | Conditional ablation of astroglial CCL2 suppresses CNS accumulation of M1 macrophages and preserves axons in mice with MOG peptide EAE. |
| Q53489843 | Continuous subcutaneous insulin infusion preserves axonal function in type 1 diabetes mellitus. |
| Q48866769 | Cortical dysfunction underlies disability in multiple sclerosis |
| Q48711123 | Cortical excitability differences in hand muscles follow a split-hand pattern in healthy controls |
| Q48881997 | Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis |
| Q36007434 | Creatine pretreatment protects cortical axons from energy depletion in vitro |
| Q35762075 | Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis |
| Q46843624 | Decreased neuronal death in Na+/H+ exchanger isoform 1-null mice after in vitro and in vivo ischemia. |
| Q41293250 | Delayed axonal degeneration in slow Wallerian degeneration mutant mice detected using diffusion tensor imaging |
| Q36968254 | Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury |
| Q37091141 | Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for molecules associated with metabolism, signaling and regulation in central nervous system mixed glial cell cultures |
| Q46978822 | Diffuse axonal damage, myelin impairment, astrocytosis and inflammatory response following microinjections of NMDA into the rat striatum |
| Q30778741 | Diffusion fMRI detects white-matter dysfunction in mice with acute optic neuritis |
| Q36377527 | Disruption of ionic and cell volume homeostasis in cerebral ischemia: The perfect storm |
| Q38732541 | Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy |
| Q28487895 | Effects of hemodiafiltration and high flux hemodialysis on nerve excitability in end-stage kidney disease |
| Q48114524 | Elevated intracellular Na+ concentrations in developing spinal neurons |
| Q52369778 | Erythropoietin Upregulates Brain Hemoglobin Expression and Supports Neuronal Mitochondrial Activity. |
| Q53429240 | Erythropoietin improves brain mitochondrial function in rats after traumatic brain injury. |
| Q46255661 | Experimental autoimmune encephalomyelitis from a tissue energy perspective. |
| Q26773166 | Fatigue in Multiple Sclerosis: Neural Correlates and the Role of Non-Invasive Brain Stimulation |
| Q36437641 | Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. |
| Q36356656 | Focal increases of axoplasmic Ca2+, aggregation of sodium-calcium exchanger, N-type Ca2+ channel, and actin define the sites of spheroids in axons undergoing oxidative stress |
| Q36158013 | Functional recovery in rats with ischemic paraplegia after spinal grafting of human spinal stem cells |
| Q28943414 | Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis |
| Q37830727 | Glutamate and ATP signalling in white matter pathology |
| Q33410173 | Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors |
| Q42745798 | Hypoxic injury of isolated axons is independent of ionotropic glutamate receptors |
| Q37252524 | In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology |
| Q28080754 | Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis |
| Q36725102 | Inhibition of neuronal degenerin/epithelial Na+ channels by the multiple sclerosis drug 4-aminopyridine |
| Q37043672 | Investigation of cytocrom c oxidase gene subunits expression on the Multiple sclerosis |
| Q27004533 | Ion channels as drug targets in central nervous system disorders |
| Q39858360 | Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. |
| Q37161778 | Loss of Na+ channel beta2 subunits is neuroprotective in a mouse model of multiple sclerosis |
| Q37207639 | Maintaining energy homeostasis is an essential component of Wld(S)-mediated axon protection |
| Q36885898 | Mathematical Models of Blast-Induced TBI: Current Status, Challenges, and Prospects |
| Q64229784 | Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis |
| Q30494010 | Mechanisms of acute axonal degeneration in the optic nerve in vivo |
| Q34292220 | Mechanisms of axonal injury: internodal nanocomplexes and calcium deregulation |
| Q43085973 | Mechanisms of axonal spheroid formation in central nervous system Wallerian degeneration |
| Q37800214 | Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis |
| Q41486306 | Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. |
| Q28389828 | Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters |
| Q36146335 | Membrane Repair: Mechanisms and Pathophysiology. |
| Q30581669 | Missense dopamine transporter mutations associate with adult parkinsonism and ADHD. |
| Q37315208 | MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis |
| Q46563454 | Mitochondrial Membrane Potential-dependent Endoplasmic Reticulum Fragmentation is an Important Step in Neuritic Degeneration. |
| Q36709397 | Mitochondrial changes within axons in multiple sclerosis |
| Q24648580 | Mitochondrial defects in acute multiple sclerosis lesions |
| Q34807873 | Mitochondrial fission augments capsaicin-induced axonal degeneration |
| Q33919516 | Mitochondrial immobilization mediated by syntaphilin facilitates survival of demyelinated axons |
| Q48223070 | Multiple mechanisms of dimethyl fumarate in amyloid β-induced neurotoxicity in human neuronal cells. |
| Q37254889 | NADH-dehydrogenase type-2 suppresses irreversible visual loss and neurodegeneration in the EAE animal model of MS. |
| Q37960093 | Na+ channelopathies and epilepsy: recent advances and new perspectives. |
| Q34587578 | Neuropathology in Drosophila membrane excitability mutants |
| Q38952007 | Neuroprotection by central nervous system remyelination: Molecular, cellular, and functional considerations |
| Q36815387 | New concepts on progressive multiple sclerosis |
| Q38868221 | Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis |
| Q37149359 | Olfactory Ensheathing Cells Rescue Optic Nerve Fibers in a Rat Glaucoma Model |
| Q38378846 | Pathological mechanisms in progressive multiple sclerosis |
| Q49382584 | Pathophysiology of primary open-angle glaucoma from a neuroinflammatory and neurotoxicity perspective: a review of the literature. |
| Q46427894 | Perinodal glial swelling mitigates axonal degradation in a model of axonal injury |
| Q36353053 | Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis |
| Q26751830 | Plasticity in the Neonatal Brain following Hypoxic-Ischaemic Injury |
| Q37244252 | Preferential neuroprotective effect of tacrolimus (FK506) on unmyelinated axons following traumatic brain injury |
| Q38713740 | Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis |
| Q47848975 | Primary paranode demyelination modulates slowly developing axonal depolarization in a model of axonal injury |
| Q31139925 | Progressive multiple sclerosis: from pathogenic mechanisms to treatment. |
| Q38046113 | Progressive multiple sclerosis: pathology and pathogenesis |
| Q33999656 | Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. |
| Q33586608 | Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial. |
| Q38197342 | Reactive metabolites as a cause of late diabetic complications |
| Q30962193 | Recent developments in multiple sclerosis therapeutics |
| Q38203770 | Relapsing and progressive forms of multiple sclerosis: insights from pathology |
| Q50282106 | Retrograde interferon-gamma signaling induces major histocompatibility class I expression in human-induced pluripotent stem cell-derived neurons. |
| Q48726185 | Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. |
| Q48612819 | Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. |
| Q53624330 | Riluzole- and Resveratrol-Induced Delay of Retinal Ganglion Cell Death in an Experimental Model of Glaucoma. |
| Q64082981 | Role of axon resealing in retrograde neuronal death and regeneration after spinal cord injury |
| Q37438390 | Role of calpains in the injury-induced dysfunction and degeneration of the mammalian axon |
| Q35846494 | Roles of white matter in central nervous system pathophysiologies |
| Q46490485 | Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. |
| Q36142247 | Sensory nerve excitability and neuropathy in end stage kidney disease |
| Q35678497 | Sensory neurons derived from diabetic rats have diminished internal Ca2+ stores linked to impaired re-uptake by the endoplasmic reticulum |
| Q30926519 | Sodium MRI of multiple sclerosis |
| Q37345123 | Sodium and potassium currents influence Wallerian degeneration of injured Drosophila axons. |
| Q34556835 | Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice. |
| Q40315187 | Testing NMDA receptor block as a therapeutic strategy for reducing ischaemic damage to CNS white matter |
| Q26782843 | The Role of Astrocytes in Multiple Sclerosis Progression |
| Q42058281 | The axon-protective WLD(S) protein partially rescues mitochondrial respiration and glycolysis after axonal injury |
| Q28295115 | The immunopathology of multiple sclerosis: an overview |
| Q37920009 | The molecular basis of neurodegeneration in multiple sclerosis |
| Q24648646 | The phosphorylated axonal form of the neurofilament subunit NF-H (pNF-H) as a blood biomarker of traumatic brain injury |
| Q35551001 | The role of environmental exposures in neurodegeneration and neurodegenerative diseases |
| Q38210510 | The role of microglial activation in disease progression |
| Q34778793 | Therapeutic potential of fluoxetine in neurological disorders |
| Q36199193 | Therapeutic potential of kainate receptors. |
| Q33610240 | Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair |
| Q43695472 | Topography of brain sodium accumulation in progressive multiple sclerosis |
| Q30816308 | Traumatic white matter injury and glial activation: from basic science to clinics |
| Q33265694 | Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. |
| Q37714086 | Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. |
| Q47577445 | White matter axon vulnerability to AMPA/kainate receptor-mediated ischemic injury is developmentally regulated. |
| Q37972980 | White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis |
Search more.